DEVELOPMENT OF A NOVEL IMMUNOTHERAPY FOR MALIGNANT MESOTHELIOMA THAT COMBINES CXCL12/CXCR4 BLOCKADE WITH A MESOTHELIN TARGETED FUSION PROTEIN

The General Hospital Corporation

Investigators